1448232-80-1 Usage
Uses
Used in Oncology:
Naquotinib is used as an anticancer agent for the treatment of non-small cell lung cancers. It is particularly effective against cancers that have developed resistance to traditional treatments due to specific mutations in the EGFR tyrosine kinase.
Used in Drug Development:
Naquotinib is used as a research compound in the development of targeted therapies for cancer treatment. Its ability to selectively inhibit EGFR tyrosine kinase, even in the presence of resistance mutations, makes it a promising candidate for further investigation and potential clinical application.
Used in Clinical Trials:
Naquotinib is used as a subject of rigorous testing and clinical trials to assess its safety, efficacy, and potential side effects. These trials are essential in determining the viability of Naquotinib as a treatment option for patients with non-small cell lung cancers.
Check Digit Verification of cas no
The CAS Registry Mumber 1448232-80-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,8,2,3 and 2 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1448232-80:
(9*1)+(8*4)+(7*4)+(6*8)+(5*2)+(4*3)+(3*2)+(2*8)+(1*0)=161
161 % 10 = 1
So 1448232-80-1 is a valid CAS Registry Number.
1448232-80-1Relevant academic research and scientific papers
PYRAZINECARBOXAMIDE COMPOUND
-
Paragraph 0428; 0492, (2014/11/11)
[Problem] A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention. The pyrazinecarboxamide compound of the present invention has an inhibitory action on an EGFR T790M mutation kinase, and can be used as an agent for preventing and/or treating EGFR T790M mutation positive cancer, in another embodiment, EGFR T790M mutation positive lung cancer, in a still other embodiment, EGFR T790M mutation positive non-small cell lung cancer, in further still another embodiment, EGFR T790M mutation protein positive cancer, in further still another embodiment, EGFR T790M mutation protein positive lung cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant cancer, in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant lung cancer, and in further still another embodiment, EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer, or the like.
